InnoCare Pharma Limited announced that Dr. Dandan Dong has been appointed as an independent non-executive Director with effect from 11 October, 2023. Dr. Dong is primarily responsible for supervising and providing independent judgement to the Board. Dr. Dong, aged 39, currently serves as the chief business officer of ArriVent Biopharma Inc. Prior to joining ArriVent Biopharma Inc., Dr. Dong worked at Vivo Capital LLC from August 2011 to July 2021, and has held various positions there, including the managing director of Vivo Capital LLC and a managing member of the general partner of Vivo PANDA Fund and Vivo Innovation Fund II, Vivo Capital's early-stage investment vehicles.

Since November 2018, Dr. Dong has been serving as a director of VISEN Pharmaceuticals which as of the date of this announcement is in the course of seeking listing of its shares on the Main Board of the Stock Exchange of Hong Kong Limited. Dr. Dong obtained her Bachelor's degree in life science from Sichuan University in July 2006. She completed the Pre-doctoral Fellowship program in infectious disease at New York University in July 2008, and obtained her Ph.D. degree in molecular microbiology from Fudan University in July 2011.

Dr. Dong has entered into a service contract with the Company for a term of three years from 11 October, 2023, subject to retirement by rotation and re-election at the annual general meeting in accordance with the articles of association of the Company. In line with the remuneration policy and the recommendation of the remuneration committee of the Company (the "Remuneration Committee"), Dr. Dong will receive a monthly director's service fee of RMB 30,000 upon the effective date of her appointment. Under the terms of the service contract, she is entitled to bonus of such amount as the Board may determine in light of the Company's business performance and the Director's individual performance after confirmation by the Remuneration Committee.